Trial intelligence / Profile preview

Cannabidiol adjunctive treatment for seizures associated with Lennox-Gastaut syndrome

2014-002940-42Phase 3Completed

Sponsor
GW Pharmaceuticals
Start
Sep 2014
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Cannabidiol adjunctive treatment with Placebo adjunctive treatment (2 arms). Started Sep 2014; status: completed.

02

Drugs

cannabidiol
03

Conditions

Lennox-Gastaut syndrome (LGS)

Beyond the preview

Go deeper on 2014-002940-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-002940-42.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call